According to Zhitong Finance App, Jingyou Pharmaceutical (00858.HK) announced that on December 30, 2025, Changchun Jingyou (an indirect non-wholly-owned subsidiary of the company with 80.46% interest) plans to buy back about 10.06% of Changchun Jingyou's shares from Changchun Handu Dingye Real Estate Planning and Sales Co., Ltd. at a cost of RMB 4.4 million. After the share repurchase is completed, the repurchased shares will be cancelled, and the shareholders' shareholders' shareholding ratio in Changchun Jingyou will increase proportionately after the shares are cancelled, so the Group's shares in Changchun Jingyou will increase to 89.46%. Following share repurchase and share cancellation, Changchun Jingyou will continue to be an indirect non-wholly-owned subsidiary of the Group.

According to Zhitong Finance App, Jingyou Pharmaceutical (00858.HK) announced that on December 30, 2025, Changchun Jingyou (an indirect non-wholly-owned subsidiary of the company with 80.46% interest) plans to buy back about 10.06% of Changchun Jingyou's shares from Changchun Handu Dingye Real Estate Planning and Sales Co., Ltd. at a cost of RMB 4.4 million. After the share repurchase is completed, the repurchased shares will be cancelled, and the shareholders' shareholders' shareholding ratio in Changchun Jingyou will increase proportionately after the shares are cancelled, so the Group's shares in Changchun Jingyou will increase to 89.46%. Following share repurchase and share cancellation, Changchun Jingyou will continue to be an indirect non-wholly-owned subsidiary of the Group.